Francisco J. Roa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco J. Roa has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aggeliki Tserga
Biomedical Research Foundation, Academy of Athens
14 shared publications - Agnieszka Latosinska
Mosaiques Diagnostics GmbH, Hannover, Germany
14 shared publications - Antonia Vlahou
Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece
14 shared publications - Florian Handle
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
14 shared publications - Frederic Romain Santer
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
14 shared publications - Harald Mischak
Department of Biomarker Research, Mosaiques Diagnostics GmbH, 30659 Hannover, Germany
14 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained with crystal violet, and the plates were scanned. A, Representative images of the colonies. B, Quantification of the colony number. Data are presented as the number of colonies related to the control and represent mean ± SEM from three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone reduces bladder cancer tumor growth in vivo. Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control (n = 6) and amiodarone-treated (n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone reduces bladder cancer tumor growth in vivo. Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control (n = 6) and amiodarone-treated (n = 6) tumor-bearing animals during a 3-week cycle treatment. Data represent mean ± SEM (Student t test; **, P < 0.01). B, Body weight of control and amiodarone-treated animals after 27 days of the experiment. Data represent mean ± SEM (Student t test; ****, P < 0.0001). C, Histologic analysis of liver, kidney, and heart sections derived from control and amiodarone-treated animals. Representative hematoxylin and eosin images are shown. D, Heatmap of the top 20 upregulated and top 20 downregulated genes identified by RNA-seq expression analysis of xenograft tumor samples. E, Top 10 significantly deregulated pathways identified by the RNA-seq analysis. F, Gene set enrichment analysis barcode plots for the top five significantly deregulated pathways. G, Heatmap showing the expression of the apoptosis-inducing ligand TNFSF10 and mitochondrially encoded genes of the electron transport chain. H, Dot plot representing the apoptosis gene set activity score derived from RNA-seq gene expression data. FC, fold change.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) and total, was analyzed by Western blot. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of the protein expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control. n.d., not determined.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Differentially expressed genes (DEGs) between muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NBIMC).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Differentially expressed genes (DEGs) between muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NBIMC).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Figure 1. Fluvoxamine, amiodarone, isradipine, and amodiaquine reduce viability in BC cell lines. A, UMUC3, HT1197, BFTC905, and RT112 cells were treated for 96 h with increasing concentrations (0–100 μM) of fluvoxamine (A), amiodarone (B), isradipine (C), and amodiaquine (D). Viability was evaluated using the CellTiter Cell Proliferation Assay. Concentration-response curves and IC50 values are shown. Data represent mean ± SEM from 3 independent experiments. h, hour; n.d., not determined.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Figure 1. Fluvoxamine, amiodarone, isradipine, and amodiaquine reduce viability in BC cell lines. A, UMUC3, HT1197, BFTC905, and RT112 cells were treated for 96 h with increasing concentrations (0–100 μM) of fluvoxamine (A), amiodarone (B), isradipine (C), and amodiaquine (D). Viability was evaluated using the CellTiter Cell Proliferation Assay. Concentration-response curves and IC50 values are shown. Data represent mean ± SEM from 3 independent experiments. h, hour; n.d., not determined.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Development of molecular signature and CMap analysis. A, A molecular signature was established through the integration of significant changes between MIBC and NMIBC derived from multiomics data (proteomics and transcriptomics), further enriched with literature-mined data. B, The signature was randomly divided into 10 sets of molecular features and used to query the CMap to predict drugs/compounds affecting the disease’s molecular signature. C, The significant negative enrichment scores for the drugs selected for subsequent in vitro investigations are depicted. GEO, Gene Expression Omnibus; MIBC, muscle-invasive bladder cancer; NMIBC, non muscle-invasive bladder cancer.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Development of molecular signature and CMap analysis. A, A molecular signature was established through the integration of significant changes between MIBC and NMIBC derived from multiomics data (proteomics and transcriptomics), further enriched with literature-mined data. B, The signature was randomly divided into 10 sets of molecular features and used to query the CMap to predict drugs/compounds affecting the disease’s molecular signature. C, The significant negative enrichment scores for the drugs selected for subsequent in vitro investigations are depicted. GEO, Gene Expression Omnibus; MIBC, muscle-invasive bladder cancer; NMIBC, non muscle-invasive bladder cancer.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Repurposing Amiodarone for Bladder Cancer Treatment
Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated using the Caspase-Glo 3/7 Assay and viability using the CellTiter cell proliferation assay. Apoptosis results were normalized to viability. Data are presented as apoptosis related to the control and represent mean ± SEM from at least three independent experiments (one-way ANOVA with Dunnett’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). B, Western blot analysis of cPARP expression after 48 hours of treatment with 0, 12.5, and 25 μmol/L amiodarone. GAPDH was used as a loading control. Blots are representative of three independent experiments. Quantification of cPARP expression (normalized by GAPDH) is indicated under each corresponding band. Values are presented as expression related to the control.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Repurposing Amiodarone for Bladder Cancer Treatment
The analysis based on the previously generated proteomics data
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Repurposing Amiodarone for Bladder Cancer Treatment
The analysis based on the previously generated proteomics data
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Repurposing Amiodarone for Bladder Cancer Treatment
File contains 2 Supplementary Figure legends
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Repurposing Amiodarone for Bladder Cancer Treatment
File contains 2 Supplementary Figure legends